Arcturus Therapeutics Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.3%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$3.86next fiscal year
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly2.0Target: Extend beyond Q2 2028
ARCT-032 Phase 2 Enrollment QuarterlyTarget: Complete enrollment of up to 20 Class I CF participants
Quarterly Revenue Quarterly2.1MTarget: Stabilize collaboration and milestone revenues
Watch Items
- ARCT-810 End of Phase 2 (EOP2) MeetingTrigger: H2 2026 regulatory feedback from FDAAction: Align pediatric clinical development strategy and initiate pivotal trial
- KOSTAIVE Commercial Rollout in JapanTrigger: 2026/2027 season 2-dose vial presentation launch by MeijiAction: Monitor commercial uptake and milestone payments from CSL Seqirus
- CSL Limited Collaboration Write-downTrigger: Approximately $430 million accounting write-down by CSLAction: Assess long-term COVID-19 vaccine economics and partnership stability
Research as of 20 Jun 2026